# A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

> **NCT01250145** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 251 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** LY333334
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01250145
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2012-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01250145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01250145, "A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01250145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*